Entities / Company
BeOne Medicines (Switzerland).
company in Basel, Switzerland
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
Gone quiet
No new reports in 90+ days-
BeOne Medicines detailed its oncology pipeline, highlighting BRUKINSA, sonrotoclax, and BGB-16673 for various patient populations.Speculative1 report
-
BeOne Medicines filed reports with the SEC and was scheduled to present at a Morgan Stanley conference.Some support3 reports
-
BeOne Medicines (Switzerland) and Stevanato Group are companies that operate in the medical and pharmaceutical sectors.Some support1 report
-
The European Commission approved the tablet formulation of BRUKINSA, which is a key growth engine for BeOne Medicines.Some support3 reports
-
BeOne Medicines received approval for its drug TEVIMBRA based on RATIONALE-315 trial results.Some support4 reports
-
High institutional ownership and potential influence from hedge funds are noted regarding BeOne Medicines (Switzerland) as of August 2025.Some support1 report
-
Lai Wang was appointed Global Head of R&D at BeOne Medicines.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around BeOne Medicines (Switzerland) this week
News at the entities that move BeOne Medicines (Switzerland) most-
Morgan Stanley Mentioned togetherEconomists at Morgan Stanley provided analysis involving the Australian Taxation Office.Moves BeOne Medicines (Switzerland)
-
Switzerland Shared contextConflict is causing soaring fuel prices in Switzerland, leading motorists to cross borders for cheaper gas and sparking political debate.Moves BeOne Medicines (Switzerland)
Connections
The 4 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Lai Wang Structural
Lai Wang serves as the Global Head of R&D at BeOne Medicines.
-
BeOne Medicines is subject to regulatory requirements and filing obligations set by the Securities and Exchange Commission of Bangladesh.
-
Morgan Stanley Mentioned together
BeOne Medicines is scheduled to present its pipeline programs at a Morgan Stanley conference.
-
Switzerland Shared context
BeOne Medicines is domiciled and operates within Switzerland, leveraging its biopharma hub status.
History
Events by the month they beganJune 2026
7 events- BeOne Medicines detailed its oncology pipeline, highlighting BRUKINSA, sonrotoclax, and BGB-16673 for various patient populations.
- BeOne Medicines filed reports with the SEC and was scheduled to present at a Morgan Stanley conference.
- BeOne Medicines (Switzerland) and Stevanato Group are companies that operate in the medical and pharmaceutical sectors.
- The European Commission approved the tablet formulation of BRUKINSA, which is a key growth engine for BeOne Medicines.
- BeOne Medicines received approval for its drug TEVIMBRA based on RATIONALE-315 trial results.
- High institutional ownership and potential influence from hedge funds are noted regarding BeOne Medicines (Switzerland) as of August 2025.
- Lai Wang was appointed Global Head of R&D at BeOne Medicines.